According to the progress of the Shanghai Stock Exchange's issuance and listing review, on August 9, the application for the initial public offering of Cisensor Technology was submitted for registration, and the company's initial public offering was approved by the listing committee of the Shanghai Stock Exchange on January 11, 2024.
The company's main business is the research and production of liquid chromatography materials for drug analysis detection and separation and purification. The underwriting institution for this issue is China Securities Co., Ltd. The company plans to issue 4072.09 million shares and raise RMB800 million.
The funds raised by this issue of the company's shares will be invested in 20,000 tons/year of biopharmaceutical separation and purification auxiliary materials, the center project, and replenishing working capital.
The financial data shows that in 2020-2022, the company's operating revenue was RMB9766.97 million, RMB1.55 billion, and RMB2.13 billion, respectively, and the net profit was RMB856.87 million, RMB2077.38 million, and RMB4713.93 million, respectively. In terms of growth, the company's operating revenue increased by 37.37% in 2022 and the net profit increased by 126.92% (Dataport).
The company's main financial indicators
Financial indicators/Time | 2022 | 2021 | 2020 |
---|---|---|---|
Operating revenue (RMB) | 212,777.30 | 154,888.71 | 9,766.97 |
National profit attributable to shareholders (RMB) | 47,113.93 | 20,774.38 | 8,568.87 |
National profit attributable to shareholders after non-recurring gains and losses (RMB) | 4,109.19 | 2,001.72 | 646.82 |
Basic earnings per share (RMB) | 0.1286 | 0.0669 | 0.0309 |
Diluted earnings per share (RMB) | |||
Weighted average return on equity (%) | 5.16 | 6.55 | 7.43 |
Cash flow from operating activities (RMB) | 28,542.26 | -70.20 | 23,142.25 |
R&D expenditure (RMB) | 23,516.65 | 21,330.01 | |
R&D expenditure as a percentage of operating revenue (%) | 15.18 | 21.84 |
Note: This article is a news report and does not constitute an investment recommendation. The stock market is risky, and investment should be cautious.
Review progress
Review progress, registration submission, initial public offering, and listing on the Science and Technology Innovation Board